Ascletis Pharma Inc.

Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication
2021-05-27
Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA
2021-05-25
Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)
2021-05-05
Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41
2021-04-14
Ascletis Announced Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentations by the International Liver Congress™ 2021
2021-04-12
Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors
2021-03-30
Ascletis’ Strategic Partner Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH
2021-03-22
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH
2021-03-09
Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH
2021-02-25
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41
2021-02-21

3

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1